Prognostic factors and skeletal‑related events in patients with bone metastasis from gastric cancer

Imura,Yoshinori; Tateiwa,Daisuke; Sugimoto,Naotoshi; Inoue,Akitomo; Wakamatsu,Toru; Outani,Hidetatsu; Tanaka,Takaaki; Tamiya,Hironari; Yagi,Toshinari; Naka,Norifumi; Okawa,Sumiyo; Tabuchi,Takahiro; Takenaka,Satoshi

doi:10.3892/mco.2020.2101

Prognostic factors and skeletal‑related events in patients with bone metastasis from gastric cancer

Authors:
- Yoshinori Imura
- Daisuke Tateiwa
- Naotoshi Sugimoto
- Akitomo Inoue
- Toru Wakamatsu
- Hidetatsu Outani
- Takaaki Tanaka
- Hironari Tamiya
- Toshinari Yagi
- Norifumi Naka
- Sumiyo Okawa
- Takahiro Tabuchi
- Satoshi Takenaka
View Affiliations

Affiliations: Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka 541‑8567, Japan, Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565‑0871, Japan, Department of Clinical Oncology, Osaka International Cancer Institute, Osaka 541‑8567, Japan, Cancer Control Center, Osaka International Cancer Institute, Osaka 541‑8567, Japan
Published online on: July 22, 2020 https://doi.org/10.3892/mco.2020.2101
Article Number: 31
Copyright: © Imura et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The number of studies on bone metastasis (BM) from gastric cancer (GC) is currently limited. Therefore, the aim of the present study was to investigate the characteristics, skeletal‑related events (SREs) and prognosis of GC in patients with BMs. Data from 60 patients with BMs from GC were retrospectively retrieved and patient‑, tumor‑ and BM‑related characteristics were analyzed. Kaplan‑Meier survival curves were analyzed using the univariate log‑rank test. Multivariate analyses were conducted using the Cox proportional hazards model. The median patient age was 63.5 years (range, 26‑83 years). Visceral or brain metastases were observed at BM diagnosis in 61.7% of the patients. Multiple BMs were detected in 83.3% and SREs occurred in 76.7% of the patients. The median overall survival (OS) after BM diagnosis and SRE occurrence was 9 months (range, 0‑43 months) and 5 months (range, 0‑36 months), respectively. On multivariate analysis, poor Eastern Cooperative Oncology Group performance status (P=0.030), the administration of chemotherapy prior to BM diagnosis (P<0.001) and no chemotherapy after BM diagnosis (P=0.002) were significant prognostic factors for unfavorable OS, whereas the non‑use of bone‑modifying agents (BMAs) was the only independent prognostic factor for poor SRE‑free survival (SRS; P=0.022). Among patients without SREs at BM diagnosis, the median SRS duration was 7 months (range, 0‑43 months). In conclusion, chemotherapy may confer a survival benefit in GC patients with BMs. In addition, the prognosis for GC patients with BMs presenting with SREs is poor, but treatment with BMAs may prevent or delay the development of SREs.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011.PubMed/NCBI View Article : Google Scholar
2	Guadagni S, Catarci M, Kinoshita T, Valenti M, De Bernardinis G and Carboni M: Causes of death and recurrence after surgery for early gastric cancer. World J Surg. 21:434–439. 1997.PubMed/NCBI View Article : Google Scholar
3	Ahn JB, Ha TK and Kwon SJ: Bone metastasis in gastric cancer patients. J Gastric Cancer. 11:38–45. 2011.PubMed/NCBI View Article : Google Scholar
4	Park HS, Rha SY, Kim HS, Hyung WJ, Park JS, Chung HC, Noh SH and Jeung HC: A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis. Oncology. 80:142–150. 2011.PubMed/NCBI View Article : Google Scholar
5	Silvestris N, Pantano F, Ibrahim T, Gamucci T, De Vita F, Di Palma T, Pedrazzoli P, Barni S, Bernardo A, Febbraro A, et al: Natural history of malignant bone disease in gastric cancer: Final results of a multicenter bone metastasis survey. PLoS One. 8(e74402)2013.PubMed/NCBI View Article : Google Scholar
6	Turkoz FP, Solak M, Kilickap S, Ulas A, Esbah O, Oksuzoglu B and Yalcin S: Bone metastasis from gastric cancer: The incidence, clinicopathological features, and influence on survival. J Gastric Cancer. 14:164–172. 2014.PubMed/NCBI View Article : Google Scholar
7	Kim YJ, Kim SH, Kim JW, Lee JO, Kim JH, Bang SM, Lee JS and Lee KW: Gastric cancer with initial bone metastasis: A distinct group of diseases with poor prognosis. Eur J Cancer. 50:2810–2821. 2014.PubMed/NCBI View Article : Google Scholar
8	Nishidoi H and Koga S: Clinicopathological study of gastric cancer with bone metastasis. Gan To Kagaku Ryoho. 14:1717–1722. 1987.PubMed/NCBI(In Japanese).
9	Choi CW, Lee DS, Chung JK, Lee MC, Kim NK, Choi KW and Koh CS: Evaluation of bone metastases by Tc-99m MDP imaging in patients with stomach cancer. Clin Nucl Med. 20:310–314. 1995.PubMed/NCBI View Article : Google Scholar
10	Nielsen OS, Munro AJ and Tannock IF: Bone metastases: Pathophysiology and management policy. J Clin Oncol. 9:509–524. 1991.PubMed/NCBI View Article : Google Scholar
11	Mundy GR: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2:584–593. 2002.PubMed/NCBI View Article : Google Scholar
12	Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 12 (Suppl)(6243S-6249S)2006.PubMed/NCBI View Article : Google Scholar
13	Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A and Seaman JJ: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 91:1191–1200. 2001.PubMed/NCBI View Article : Google Scholar
14	Riihimaki M, Hemminki A, Sundquist K, Sundquist J and Hemminki K: Metastatic spread in patients with gastric cancer. Oncotarget. 7:52307–52316. 2016.PubMed/NCBI View Article : Google Scholar
15	Coleman RE: Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 27:165–176. 2001.PubMed/NCBI View Article : Google Scholar
16	Lim SM, Kim YN, Park KH, Kang B, Chon HJ, Kim C, Kim JH and Rha SY: Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. BMC Cancer. 16(385)2016.PubMed/NCBI View Article : Google Scholar
17	Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol. 24:4991–4997. 2006.PubMed/NCBI View Article : Google Scholar
18	Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 358:36–46. 2008.PubMed/NCBI View Article : Google Scholar
19	Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, et al: Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 30:1513–1518. 2012.PubMed/NCBI View Article : Google Scholar
20	Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, et al: Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): An open-label, phase 3 randomised controlled trial. Lancet Oncol. 15:78–86. 2014. View Article : Google Scholar
21	Mikami J, Kimura Y, Makari Y, Fujita J, Kishimoto T, Sawada G, Nakahira S, Nakata K, Tsujie M and Ohzato H: Clinical outcomes and prognostic factors for gastric cancer patients with bone metastasis. World J Surg Oncol. 15(8)2017. View Article : Google Scholar
22	Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, et al: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer. 98:1735–1744. 2003.PubMed/NCBI View Article : Google Scholar
23	Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, et al: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet. 377:813–822. 2011.PubMed/NCBI View Article : Google Scholar
24	Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol. 28:5132–5139. 2010.PubMed/NCBI View Article : Google Scholar